Pfizer Continues Positive Data Readouts For JAK Inhibitor Abrocitinib In Eczema

 
• By Joseph Haas

A second Phase III JADE study showed statistically significant skin clearance and reduced pruritus in atopic dermatitis, although safety is harder to evaluate for now. A filing planned for 2020 will include results from a cross-study comparison evaluating abrocitinib versus Dupixent.

woman in a laboratory microscope with microscope slide in hand.toned image.
Pfizer continues to build a case for its JAK1 inhibitor in atopic dermatitis

More from Clinical Trials

More from R&D